Skip to main content

CLDX

Stock
Health Care
Biotechnology

Performance overview

CLDX Price
Price Chart

Forward-looking statistics

Beta
0.75
Risk
52.54%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Company info

SectorHealth Care
IndustryBiotechnology
Employees161
Market cap$2.3B

Fundamentals

Enterprise value$681.3M
Revenue$7.6M
Revenue per employee
Profit margin0.00%
Debt to equity0.49

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$2.70
Dividend per share
Revenue per share$0.11
Avg trading volume (30 day)$27M
Avg trading volume (10 day)$28M
Put-call ratio

Macro factor sensitivity

Growth-5.4
Credit+7.7
Liquidity+3.0
Inflation-5.5
Commodities-3.1
Interest Rates-2.1

Valuation

Dividend yield0.00%
PEG Ratio-6.81
Price to sales193.24
P/E Ratio-6.81
Enterprise Value to Revenue90.13
Price to book2.08

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day
Ex. dividend day

News

Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.56 per share a year ago.

Zacks Investment Research (May 8, 2025)
Read How Cantor Views Celldex Therapeutics' Barzolvolimab Data

Celldex Therapeutics Inc's (NASDAQ: CLDX) shares closed almost 16% down on Friday after releasing Phase 1b study data of barzolvolimab. Cantor says the main reason for stock being down is the four patient adverse events on the generally transient, asymptomatic, and mild.

Benzinga (July 5, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free